Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferreira, C. G.
Right arrow Articles by Giaccone, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferreira, C. G.
Right arrow Articles by Giaccone, G.
[Cancer Research 60, 7133-7141, December 15, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

Chemotherapy Triggers Apoptosis in a Caspase-8-dependent and Mitochondria-controlled Manner in the Non-Small Cell Lung Cancer Cell Line NCI-H460

Carlos G. Ferreira1, Simone W. Span, Godefridus J. Peters, Frank A. E. Kruyt and Giuseppe Giaccone2

Department of Medical Oncology, Academic Hospital Vrije Universiteit Amsterdam, 1081HV Amsterdam, the Netherlands


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Chemotherapy-induced apoptosis is generally thought to be dependent on a pathway headed by caspase-9. This model is primarily based on studies performed in leukemia cells; however, little is known about caspase cascades in relatively resistant solid tumor cells, including non-small cell lung cancer (NSCLC) cells. Using the NSCLC cell line NCI-H460 (H460), here, we studied the effect of stable expression of various caspase inhibitors on apoptosis induced by the anticancer drugs cisplatin, topotecan, and gemcitabine. Interestingly, overexpression of caspase-9S and X-linked inhibitor of apoptosis (XIAP), both able to inhibit caspase-9 activity, failed to block apoptosis. In contrast, stable expression of caspase-8 inhibitors, such as cytokine response modifier A (CrmA) and dominant-negative caspase-8, almost completely abrogated apoptosis and also enhanced clonogenic survival. Caspase-8 activation in H460 cells was not mediated by death receptors, inasmuch as overexpression of dominant-negative Fas-associated death domain (FADD-DN) did not prevent procaspase-8 cleavage and subsequent apoptosis. However, stable expression of Bcl-2 and Bcl-xL did suppress these apoptotic events, including the release of cytochrome c from mitochondria, which was observed in drug-treated H460 cells. In the NSCLC cell line H460, we, thus, provide evidence for the existence of a novel drug-inducible apoptotic pathway in which activation of caspase-8, and not of caspase-9, forms the apical and mitochondria-dependent step that subsequently activates the downstream caspases.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
NSCLC3 remains a disease with poor prognosis despite recent advances made in early diagnosis and treatment. More than 75% of the patients with NSCLC prove to be potential candidates for chemotherapy at some point during the course of their disease because of the development of metastases (1) . However, chemotherapy still shows poor response rates in NSCLC patients, with relatively short duration and rare complete remissions. Identifying the molecular determinants of sensitivity and resistance to chemotherapy in NSCLC as well as in other solid tumor types may help improve its efficacy.

Although the primary intracellular targets and the pharmacological mechanisms of action of the anticancer drugs vary, it has become evident that drug-induced cell kill is, at least partially, mediated by programmed cell death or apoptosis (2) . Relevant progress has been made in the understanding of the events underlying drug-induced apoptosis, and several molecules have been implicated in this process. Among them, a family of aspartatic-specific cysteine-proteases named caspases (3) are the central executors of the apoptotic process (4 , 5) . Thus far, 14 family members have been cloned in mammals, but not all of them seem to be directly involved in apoptosis (6) . Caspases are synthesized as inactive zymogens (Mr 30,000–50,000) that possess three domains: an NH2-terminal domain; a large subunit (Mr ~20,000); and a small subunit (Mr ~10,000; Ref. 5 ). In general, the process of caspase activation requires a proteolytic processing between domains, followed by an assembly of the subunits to generate an active tetramer (4, 5, 6) .

Caspases are activated in a cascade fashion. It has been proposed that a proapoptotic signal can activate an initiator or upstream caspase, which usually possesses a long prodomain such as caspases-8, -9, and -10. In turn, these initiators can activate the effector or downstream caspases, including caspase-3, -6, and -7, which leads to the biochemical and morphological changes that are characteristic of apoptosis (7) . To date, two major caspase pathways or cascades, headed by caspases-8 and -9, have been described and shown to mediate distinct sets of signals (7, 8, 9, 10) . The cascade led by caspase-8 is involved in death-receptor-mediated apoptosis such as the one triggered by Fas, TNF, and TRAIL. On activation, these receptors recruit FADD, which in turn binds to procaspase-8, which leads to cleavage into its active form (11 , 12) . The subsequent activation of the effector caspases occurs either directly or after an amplification step involving mitochondria (13) . On the other hand, the caspase pathway headed by caspase-9 is thought to mediate chemical-induced apoptosis. This cascade is triggered by the cytochrome c release from mitochondria, leading to the formation of a complex with Apaf-1 that via its caspase recruitment domain (CARD) binds to procaspase-9 (14) . This complex, called apoptosome (15) in the presence of dATP can activate procaspase-9, which in turn activates effector caspases (16) . In contrast to the caspase-8 cascade, in which the role of mitochondria may vary between different cell types (13) , the caspase-9 pathway is clearly mitochondria-dependent.

The Bcl-2 family of proteins plays a crucial role in the function of mitochondria during the apoptotic process (17) . Overexpression of the antiapoptotic molecules Bcl-2 or Bcl-xL has been reported to cause resistance to anticancer drugs (18 , 19) . These molecules have the capacity to inhibit apoptosis by preventing permeability transition (PT) and/or by stabilizing the barrier function of the outer mitochondrial membrane (20 , 21) . Stabilization of the mitochondria pores abrogates the release of cytochrome c (22) , thereby preventing the activation of procaspase-9.

Besides the action of Bcl-2 family members, other more direct mechanisms of caspase inhibition have been identified. Viruses are known to produce potent caspase inhibitors, such as CrmA made by cowpox virus that preferentially inhibits caspase-1 and caspase-8 (23) . On the other hand, the baculovirus p35 protein is an example of a broad range inhibitor that blocks multiple caspases (24) . On the basis of sequence similarity toward p35, human homologues of IAPs have been identified such as XIAP, cIAP1, cIAP2 and survivin (25, 26, 27) . They have been shown to be able, in the case of XIAP, cIAP1, and cIAP2, to inhibit not only effector caspases but also the initiator caspase-9 (28) .

Current available data on the molecular mechanism underlying the sequential activation of caspases has led to a model in which caspase-9 is activated on chemotherapy and caspase-8 is activated by death receptor signaling (7, 8, 9, 10) . Nevertheless, some reports have described the activation of procaspase-8 after chemotherapy (29, 30, 31, 32, 33) . However, this activation seems to be a downstream and secondary event that follows caspase-9 activation (7 , 29, 30, 31) . In addition, it should be noted that most of these studies were performed in leukemia cell lines or in cell-free extracts, and that relatively little data are available on the activation of caspases in chemotherapy-induced apoptosis in solid tumor cells.

To obtain more insight in the molecular mechanisms underlying drug sensitivity in NSCLC cells, here we examined the caspase cascades involved in triggering apoptosis in the NSCLC cell line H460. Our results—obtained by means of various biochemical assays, including caspase cleavage and activity assays, and by using selective peptide and molecular inhibitors of caspases—clearly point to a central role for caspase-8 in chemotherapy-induced apoptosis in H460 cells.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Chemicals.
Drugs were provided as pure substances. Stock solutions of cisplatin (Bristol-Myers Squibb, Woerden, the Netherlands) and gemcitabine (Eli Lilly Research Laboratories, Indianapolis, IN) were made in PBS; topotecan (SmithKline-Beecham Pharmaceuticals, Herts, United Kingdom) was dissolved in water. For each experiment, the stock solutions of the drugs (Table 1)Citation were freshly diluted in culture medium to the indicated final concentration. The caspase-inhibitors Z-VAD-fmk, used at a final concentration ranging from 50 to 100 µg/ml and the preferential caspase-8 inhibitor IETD-fmk, added to a final concentration of 20–40 µg/ml, were used 2 h prior to drug exposure. Both of the inhibitors were purchased from Enzyme System Products (Livermore, CA). In some experiments, the caspase-3-like inhibitor DEVD-CHO (Calbiochem, San Diego, CA) was used at a final concentration of 50–100 µg/ml.


View this table:
[in this window]
[in a new window]
  		Table 1 Drug concentration (nM) responsible for 50 and 80% growth inhibition (IC50 and IC80)

Results depicted were obtained by MTT assay at 72 h and represent a mean of three experiments with SD <=10%.

 
Expression Vectors.
The cDNAs encoding CrmA wild type, loss of function mutant CrmA (T291R), Bcl-2, Bcl-xL, subcloned into the expression vector pEFFLAGpGKpuro, were described previously (32 , 33) . pcDNA3 vectors encoding caspase-9S, active site mutant caspase-8 (Flice-DN or caspase-8-DN) and FADD-DN have also been described elsewhere (34, 35, 36) . The cDNA encoding myc-tagged-XIAP was excised from pCS3MT-XIAP (37) and subcloned into pcDNA3.

Cell Lines and Transfection.
The human NSCLC cell lines NCI-H460 (H460), NCI-H322 (H322), and SW1573 and Jurkat-T-leukemia cells were used in the experiments. Cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated FCS (Life Technologies, Inc., Breda, the Netherlands), 2 mM L-glutamine, 50 IU/ml penicillin, and 50 µg/ml streptomycin, and grown at 37°C in a humidified atmosphere with 5% CO2. The cell lines were tested regularly for the absence of Mycoplasma infection. Cells from exponentially growing cultures were used in all of the experiments.

For the generation of stable transfectants, H460 cells were transfected with 10 µg cDNA, using Superfect reagent (Life Technologies, Inc.) according to the manufacturer’s protocol. After 24 h, cells from each transfection were split into five separate culture dishes to ensure that independent lines were established. Selection was made using increasing concentrations of puromycin (Sigma, Zwijndrecht, the Netherlands) ranging from 1 to 2 µg/ml or 200–400 µg/ml Geneticin (Life Technologies, Inc.), depending on the transfected plasmid used. Independent clones were collected and allowed to grow in six-well plates. Clones were tested for the expression of the constructs by Western blotting and were selected for use in the desired experiments.

Cell Death Measurement.
Cells were plated at a density of 5 x 106 cells in 75-cm2 tissue culture flasks (Costar, Cambridge, MA) 24 h before treatment. Cells were incubated for 4–72 h with IC50s or IC80s of cisplatin, topotecan, or gemcitabine (Table 1)Citation in the presence or the absence of peptide inhibitors of caspases when indicated. The analysis of apoptotic cells was performed as described previously (38) . Briefly, the extent of cell death was determined by PI staining of hypodiploid DNA or by annexin V-FITC and 7-AAD double staining. For the PI staining, 3 x 105 cells were resuspended in Nicoletti buffer as described previously (39) and analyzed by FACScan (Becton Dickinson, Mount View, CA). The fraction of cells with sub-G1 DNA content was assessed by the Lysis program (Becton Dickinson). Annexin V staining was performed according to the manufacturer’s protocol (Nexins Research, Kattendijk, the Netherlands). After incubation with annexin V, 10 µl of 7-AAD (PharMingen, San Diego, CA) was added and analysis was performed on FACScalibur using CELLQuest software (Becton Dickinson). The percentage of specific apoptosis was calculated by subtracting the percentage of spontaneous apoptosis of the relevant controls from the total percentage of apoptosis.

Growth-Inhibition Assays.
Cytotoxicities to cisplatin, topotecan, and gemcitabine were assessed by MTT assay basically as described previously (38 , 41) . In brief, a suspension of 10,000 cells/100 µl of medium was added to each well of flat- or U-bottomed 96-well plates (Costar, Corning, NY) and allowed to grow. Twenty-four h later, drugs were made up in medium and eight different concentrations were added to the plates at a volume of 100 µl per well, and plates were incubated for 72 h with drugs. Then 20 µl of a solution of 5 mg/ml MTT (Sigma Chemicals, St. Louis, MO) were added to each well and incubated for another 4 h at 37°C. Plates were then centrifuged at 1000 rpm at 4°C for 5 min, and the medium was carefully discarded. The formazan crystals were dissolved in 100 µl of DMSO (ACROS Organics, Geel, Belgium) and absorbance was read at 540 nm using Spectra Fluor (Tecan, Salzburg, Austria). Absorbance values were expressed as a percentage of untreated controls and concentrations resulting in IC50 and IC80 were calculated. The IC50 and IC80 values represent the means of at least three independent experiments.

Clonogenic assays were performed essentially as described previously (40) . H460 cells were seeded in triplicate into six-well plates at a concentration of 300 cells per well. After 24 h, drugs (cisplatin, topotecan, or gemcitabine) were added at final concentrations of IC50 or IC80 (Table 1)Citation for 24–72 h. After drug removal, cells were washed twice with PBS and allowed to proliferate in fresh medium. Colonies were counted when they reached the size of 50–100 cells, after staining with 0.1% crystal violet in 0.9% saline for 30 min at room temperature. The number of colony-forming units in treated cultures was expressed as the percentage of untreated controls.

Electrophoresis and Western Blotting.
Western blot analysis was performed essentially as described previously (38) . In brief, from each sample, 25 µg of protein per lane were separated on 8–15% SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes (Amersham, Braunschweig, Germany). Subsequently, membranes were incubated overnight at 4°C in a solution of PBS supplemented with 5% nonfat dry milk. For immunodetection, the following antibodies were used: anti-caspase-3, anti-caspase-7, and anti-FADD mouse mAbs (Transduction Laboratories, Lexington, KY); anti-caspase-8 mAb (Immunotech, Marseille, France); anti-Flag mAb (Stratagene, La Jolla, CA); anti-cytochrome c mAb and anti-caspase-9 polyclonal antibody (PharMingen, San Diego, CA); anti-Myc mAb and anti-Bcl-xL polyclonal antibody (Santa Cruz Biotechnologies, Santa Cruz, CA), Bcl-2 mAb (Dako, Santa Barbara, CA), and rabbit Apaf-1 polyclonal antibody (provided by Dr. Xiadong Wang). After 2-h incubation with the primary antibody in dilutions that ranged from 1:500 to 1:2000, membranes were washed in TBST [10 mM Tris-HCl (pH 8.0), 0.15 M NaCl, and 0.05% Tween 20], followed by horseradish peroxidase-conjugated goat-antimouse or goat-antirabbit antibody. ECL (Amersham, Braunschweig, Germany) was used for detection, and protein expression was quantified by densitometry of autoradiographs (Bio-Rad, Model GS-690, Imaging densitometer, Richmond, CA). Protein loading equivalence was assessed by the expression of ß-actin.

Preparation of Cytosolic Extracts.
Cytosolic extracts were prepared essentially as described by Deveraux et al. (28) . Briefly, cells were pelleted by centrifugation after being washed once with ice-cold buffer A [20 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, and 1 mM DTT]. Subsequently, cell pellets were resuspended in two volumes of buffer A, incubated for 20 min on ice, and disrupted by 20 passages through a 26-gauge needle. Cell extracts were clarified of mitochondria by centrifugation at 20,000 x g for 30 min at 4°, and the harvested cytosolic extracts were stored at -80°C.

Fluorimetric Assay for Caspase Activity.
Spectrofluorimetric assays of proteolytic activity were carried out using synthetic fluorogenic substrates DEVD-AFC to measure caspase-3-like or effector caspase activity and IETD-AFC to assess initiator caspase activity. Both kits were purchased from Clontech Laboratories Inc. (Palo Alto, CA). Assays for caspase-9 activity were performed using the synthetic fluorogenic substrate LEHD-AFC (MBL Co., Nagoya, Japan). Experiments were performed according to the manufacturer’s protocols. Fluorescence was detected using a fluorometer equipped with a 400-nm excitation and a 505-nm emission filter (Spectra Fluor Tecan, Salzburg, Austria). Fold-increase in the protease activity was determined by comparing the levels of the treated cells with untreated controls. The values obtained are depicted in Figs. 1ECitation , 4FCitation , 6CCitation , and 7BCitation as fluorescence units (F.U. x 106).



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 1. Inhibition of caspase-9 fails to affect drug-induced apoptosis in H460 cells. H460 cells were stably transfected with vectors expressing myc-tagged XIAP (XIAP-myc), caspase-9S, or the empty vector. A, Western blot analysis demonstrating the ectopic overexpression of caspase-9S or XIAP-myc in the selected clonal cell lines compared with empty vector transfected cells (Vctr). B, H460 cells transfected with caspase-9S, XIAP-myc or the empty vector (Vctr) were exposed to IC80 concentrations of cisplatin. After 48 h, the percentage of apoptotic cells was analyzed by PI staining and compared with untreated cells (Control). C, analysis of DEVD-AFC cleavage in H460 cells overexpressing caspase-9-inhibitors. Indicated H460 transfectants were exposed to IC80 concentrations of cisplatin and DEVD-AFC cleavage was determined 48 h after treatment and compared with untreated controls. The amount of DEVD-AFC cleavage is depicted in fluorescence units (F.U. x 106). D, Western blots showing the expression of caspase-9 and Apaf-1 in H460 cells and Jurkat-T-leukemia cells. ß-actin expression was determined as a control for loading. E, caspase-9 activity in H460 and Jurkat-T cells on cisplatin exposure and measured by LEHD-AFC cleavage. Untreated control cells were included to determine the fold-increase in proteolytic activity on exposure to the drug. After 48 h the amount of LEHD-AFC cleavage was determined (F.U. x 106). All of the results are represented as the mean of at least three independent experiments.

 


View larger version (41K):
[in this window]
[in a new window]
  		Fig. 4. Caspase-8 activation in chemotherapyinduced apoptosis in H460 is mitochondria-dependent. A, H460 cells were treated with IC80 concentrations of cisplatin in the presence (+) or absence (-) of the caspase peptide inhibitors IETD-fmk or zVAD-fmk. Cytochrome c (cyt-c) release from mitochondria was determined in cytosolic extracts 48 h posttreatment by Western blotting. ß-actin mAb was used for loading control. B, examination of Bcl-2 and Bcl-XL overexpression in H460-derived stable transfectants, as shown by Western blotting. C, Bcl-2 and Bcl-XL, but not CrmA-WT, prevent cisplatin-induced cytochrome c (cyt-c) release. The indicated treated (+) or untreated (-) stable transfectants were analyzed by Western blotting for cytochrome c release. ß-actin mAb was used as a control for the amount of protein loaded. D, overexpression of Bcl-2 and Bcl-XL suppresses cisplatin-induced apoptosis in H460 cells. Untreated cells served as controls for determining background levels of apoptosis (Control). E, procaspase-8 cleavage in H460 cells stably expressing Bcl-2 or Bcl-XL. Cells were cultured with (+) or without (-) cisplatin, and after 48 h, procaspase-8 processing was examined by Western blotting. F, caspase-8 activity, as determined by IETD-AFC cleavage, is suppressed in Bcl-2 overexpressing H460 cells. IETD-AFC was measured 48 h after treatment with IC80 concentrations of cisplatin. The level of IETD-AFC cleavage is represented by fluorescence units (F.U. x 106).

 


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 6. Blocking of caspase-8 activation during drug-induced apoptosis in H460 cells prevents downstream apoptotic events. A, Western blot showing the effect of treatment with the caspase-3-like inhibitor DEVD-CHO on procaspase-8 cleavage on 48 h treatment with cisplatin. B, cleavage of PARP was analyzed as an indirect marker for caspase-3-like activity. H460 cells transfected with CrmA WT, CrmA mut, caspase-8-DN, or an empty vector were untreated (-) or exposed to IC80 concentrations of cisplatin (+) prior to Western blotting. Cleaved PARP is represented by the Mr 89,000 (89kDa) band, which is the cleaved product of the intact form of Mr 113,000 (113kDa). C, overexpression of CrmA WT suppresses the activation of caspase-3-like activity. Indicated stable transfectants were treated with cisplatin, and the proteolytic cleavage of DEVD-AFC was measured 48 h after treatment. The level of DEVD-AFC cleavage is depicted in fluorescence units (F.U. x 106).

 


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 7. Cisplatin-induced apoptosis is suppressed by the preferential caspase-8 peptide inhibitor IETD-fmk and triggers high caspase-8 activity in different NSCLC cell lines. A, the NSCLC cell lines H460, H322, and SW1573 were treated with cisplatin in the presence or absence of the preferential caspase-8 inhibitor IETD-fmk or the broad-spectrum caspase inhibitor zVAD-fmk. Jurkat-T cells served as a control, representing cells that are not dependent on caspase-8 in drug-induced apoptosis. B, caspase-8 activity triggered on exposure to cisplatin or Fas was determined by IETD-AFC cleavage in three NSCLC cell lines (H460, H322, and SW1573) and was compared with the results observed in Jurkat cells. Fas-induced apoptosis was used as a positive control for caspase-8 activation. The amount of IETD-AFC cleavage was measured at 48 h and is depicted in fluorescence units (F.U. x 106). The mean of at least three independent experiments is shown.

 
Statistics.
Quantitative experiments were analyzed by the Student’s t test. All of the Ps resulted from the use of two-sided tests and were considered significant when <0.05.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Stable Expression of Caspase-9 Inhibitors Fail to Protect H460 Cells from Drug-induced Apoptosis.
We started the investigation by analyzing the role of caspase-9 in the NSCLC cell line H460. These cells, as well as other NSCLC cell lines have been previously characterized in our laboratory with respect to their sensitivity to drug- and Fas-induced apoptosis (38 , 41) . H460 cells were selected as representatives for NSCLC cells because of their favorable transfection properties. Stable transfectants were generated using vectors expressing caspase-9S, a spliced variant of caspase-9 with dominant-negative activity (34) , or the IAP family member XIAP (Fig. 1A)Citation and exposed to cisplatin. Interestingly, as shown in Fig. 1BCitation , caspase-9S did not block drug-induced apoptosis in H460 cells (P = 0.72). In line with this observation, overexpression of the caspase-9 inhibitor XIAP led only to minimal protection against drug-induced apoptosis (Fig. 1BCitation ; P = 0.30). The lack of effect of overexpression of caspase-9S and XIAP on apoptosis was independent of the anticancer agent (cisplatin, topotecan, and gemcitabine), drug concentration (IC50 and IC80), duration of exposure (4–72 h), or clone used in the experiments (data not shown). Moreover, the caspase-3-like or effector activity induced by these drugs was not affected in cells overexpressing caspase-9S (P = 0.27), and only slightly decreased in cells transfected with XIAP (Fig. 1CCitation ; P = 0.20), which suggests that the effector activity triggered by chemotherapy is caspase-9-independent in H460 cells. The small percentage of inhibition provided by the overexpression of XIAP on drug-induced apoptosis and DEVD-AFC cleavage, compared with the absence of blockade achieved by the overexpression of caspase-9S, might be interpreted as an additional effect of XIAP on caspases-3 and -7, also known targets of this IAP member (28) . As shown in Fig. 1DCitation , H460 cells express similar levels of caspase-9 and Apaf-1 as compared with Jurkat-T-leukemia cells, used as a control due to their well-established dependency on caspase-9 activation for chemical-induced apoptosis (28) . However, upon exposure to chemotherapy, no substantial cleavage of LEHD-AFC, a preferential substrate for caspase-9 (42) , was observed above the control levels in H460 cells (P = 0.2), whereas, in Jurkat-T-leukemia cells, a 6-fold increase was found (Fig. 1ECitation ; P = 0.005). Interestingly, as shown in Fig. 1ACitation , the overexpression of caspase-9S in H460 cells was accompanied by a reduction in the levels of endogenous caspase-9. Nevertheless, the overexpression of caspase-9S and the reduction on the caspase-9 protein had no effect on the levels of LEHD-AFC cleavage induced by chemotherapy in these cells when compared with H460 cells transfected with an empty vector (data not shown). Taken together, these results indicate that, in H460 cells, caspase-9 is not instrumental in mediating chemotherapy-induced apoptosis.

Inhibition of Caspase-8 Suppresses Drug-induced Apoptosis.
In a previous study, we observed chemotherapy-induced caspase-8 activation that was independent of Fas/FasL signaling in NSCLC cells (38) . To further examine the relation between caspase-8 activation and drug-induced apoptosis, we engineered H460 cells to overexpress the caspase-1 and -8 inhibitor CrmA, or a mutated and inactive derivative, CrmA-mut (32) , as a control (Fig. 2A)Citation . CrmA has been shown to be a potent inhibitor of apoptosis induced by the TNF family of receptors but a poor inhibitor of apoptosis triggered by other stimuli, such as chemotherapeutic agents (32 , 43) . In contrast to these reports, an analysis of apoptosis in H460 cells overexpressing CrmA demonstrated at least 90% protection against cisplatin-induced cell death (P = 0.002), whereas no protection was observed in cells transfected with the loss-of-function CrmA-mut (P = 0.65), or with the empty vector (Fig. 2B)Citation . The inhibitory effect of CrmA are known to be mediated by pseudosubstrate sequences in the protein that are preferential for caspase-1 and -8 (32) ; however, some effects on caspases-9, -10, and -4 cannot be completely discarded (44) . Therefore, we examined the effect of expression of DN-acting caspase 8, a more specific inhibitor of caspase-8 (35) , on chemotherapy-induced apoptosis in H460 cells (Fig. 2C)Citation . Stable transfection with caspase-8-DN blocked 70% of drug-induced apoptosis (Fig. 2Citation D; P = 0.0031), thus further substantiating the results obtained with CrmA and pointing to a crucial role of caspase-8 in this process. In both CrmA- and caspase-8-DN-overexpressing H460 cells, a similar inhibitory pattern was observed on use of other drugs (topotecan and gemcitabine), drug concentration (IC50), or prolonged times of exposure (data not shown). Furthermore, the results were consistent in independently selected transfectants that overexpressed either CrmA or caspase-8-DN, or when the annexin V and 7-AAD double-staining method was used to assess apoptosis (results not shown).



View larger version (36K):
[in this window]
[in a new window]
  		Fig. 2. Blockade of caspase-8 protects H460 cells from apoptosis induced by chemotherapy. A, Western blot showing the expression of the indicated proteins in H460 cells stably transfected with vectors expressing functional Flag-tagged CrmA (CrmA-WT-flag), a loss of function CrmA mutant (CrmA-mut-flag), and the empty vector (Vctr). Two independent clones with different levels of CrmA-WT expression were selected for the experiments. B, CrmA-WT suppresses apoptosis in H460 cells treated with IC80 concentrations of cisplatin. Untreated cells for each transfectant that is indicated served as a control for background levels of apoptosis (Control). C, Western blot showing two independently obtained clones of H460 cells stably expressing a DN form of caspase-8 (caspase-8-DN). Empty vector-transfected cells were used as control (Vctr). D, DN caspase-8 inhibits cisplatin-induced apoptosis. Cells were exposed to IC80 concentrations of cisplatin, and apoptosis was monitored after 48 h. All of the results depicted represent a mean of at least three independent experiments.

 
Chemotherapy-induced Caspase-8 Activation Does Not Require Death Receptors.
As mentioned earlier, caspase-8 has been shown to be the apical caspase in death-receptor-induced apoptosis (11 , 12) . We previously reported the absence of Fas/FasL activation during drug-induced apoptosis in lung cancer cells (38) . Nonetheless, caspase-8 can be recruited and activated by other death-receptors such as TNF and DR5 (45) . In addition, it has been shown that these death-receptors use FADD as an adaptor molecule in the processing of caspase-8 (46) . To exclude the possible involvement of other death receptors such as TNF and DR5 in the activation of caspase-8 on anticancer drug treatment, we generated H460 cells overexpressing a DN form of FADD (Ref. 36 ; Fig. 3ACitation ). As expected, FADD-DN blocked more than 80% of Fas-induced apoptosis in H460 cells; however, it provided no protection against chemotherapy-induced cell death (P = 0.22; Fig. 3BCitation ). Furthermore, as determined by Western blotting, cleavage of caspase-8 was not suppressed in cells overexpressing FADD-DN (Fig. 3C)Citation . These findings demonstrate that caspase-8 activation and concomitant drug-induced apoptosis in H460 cells do not require the activity of FADD-containing receptor signaling complexes.



View larger version (30K):
[in this window]
[in a new window]
  		Fig. 3. Caspase-8 activation and drug-induced apoptosis in H460 cells occurs independently from death receptor activation. A, Western blot showing overexpression of DN FADD (FADD-DN), compared with the expression found in empty vector-transfected H460 cells (Vctr). B, stable transfectants were exposed to IC80 concentrations of cisplatin, and the percentage of apoptotic cells was determined after 48 h and compared with untreated cells (Control). As a positive control, cells were exposed to the Fas agonistic antibody CH-11 to demonstrate that FADD-DN overexpression blocks Fas death-receptor-mediated signaling. C, caspase-8 cleavage in FADD-DN- or empty vector-transfected cells. Caspase-8 processing was detected by Western blotting, after culturing the cells in the presence (+) or absence (-) of IC80 concentrations of cisplatin for 48 h. Cleaved products of caspase-8 are indicated.

 
Drug-induced Caspase-8 Activation Is Controlled by Mitochondria in H460 Cells.
The results obtained thus far suggest that caspase-8 may function as an apical caspase in the pathway that triggers apoptosis that is induced by chemotherapeutic agents in H460 cells. In analogy with drug-induced caspase 9 activation, we investigated a possible role for mitochondria in the activation of procaspase-8. First, we examined the effect of cisplatin treatment on the release of cytochrome c from mitochondria. As shown in Fig. 4ACitation , increased levels of cytochrome c are clearly evident in the cytosolic fraction 48 h after treatment. This release preceded caspase activation because exposure of the cells to the preferential caspase-8-inhibitor IETD-fmk or the broad-spectrum caspase inhibitor zVAD-fmk did not block this process (Fig. 4A)Citation . Next, cytochrome c release was monitored in H460 cells stably expressing CrmA or the antiapoptotic Bcl-2 or Bcl-xL proteins (Fig. 4B)Citation . CrmA did not affect cytochrome c release; however, this release was almost completely blocked in Bcl-2- and Bcl-xL-expressing cells in comparison with untreated controls (Fig. 4C)Citation . As predicted from this finding, cisplatin-induced apoptosis was strongly suppressed by both Bcl-2 and Bcl-xL (Fig. 4D)Citation ; in Bcl-2-expressing cells, a complete block of apoptosis was detected (P = 0.001), whereas Bcl-xL overexpression resulted in an approximately 85% reduction in cell death (P = 0.006). Moreover, Bcl-2 also blocked the processing of caspase-8 and IETD proteolytic activity (Fig. 4, E and F)Citation . Similar results were obtained on the use of topotecan or gemcitabine in these experiments (data not shown).

It has been reported that caspase-8 can be activated by caspases-9 in a mitochondria-controlled manner (29) . Although we showed that caspase-9 is not involved in the apoptotic process in H460 cell (Fig. 1)Citation , we wanted to further exclude this alternative. In H460 cells that overexpressed caspase-9S, caspase-8 cleavage remained clearly detectable after cisplatin treatment (Fig. 5)Citation . Taken together, these data provide strong evidence for the existence of a mitochondria-dependent pathway that is able to activate procaspase-8, independently from caspase-9, during anticancer drug-induced apoptosis.



View larger version (26K):
[in this window]
[in a new window]
  		Fig. 5. Caspase-8 cleavage is not dependent on caspase-9 activity in drug-induced apoptosis in H460 cells. Cells stably transfected with the caspase-9S expression vector or with the empty vector (Vctr) were treated (+) or not treated (-) with IC80 concentrations of cisplatin. After 48 h, the cleavage of procaspase-8 was analyzed by Western blotting. The indicated bands of Mr 43,000 (p43) and 41,000 (p41) represent the intermediate products of the cleaved proform.

 
Caspase-8-dependent Activation of Effector Caspases.
It has been suggested that caspase-8 can be activated downstream of caspase-3 (29) . To rule out this possibility and to further order the sequence of events in drug-induced apoptosis in H460 cells, we exposed the cells to the caspase-3-like inhibitor DEVD-CHO during cisplatin treatment. As shown in Fig. 6ACitation , this inhibitor had no effect on caspase-8 cleavage, although we could observe a 30–50% decrease in apoptosis (result not shown). In addition, a more downstream event, such as PARP cleavage, was prevented by overexpression of CrmA and caspase-8-DN (Fig. 6B)Citation , likely attributable to the suppression of DEVD-like activity triggered by cisplatin exposure in these stable transfectants (Fig. 6C)Citation . These results show that effector caspases are activated after the cleavage of procaspase-8 in drug-induced apoptosis in H460 cells.

Drug-induced Apoptosis Is Inhibited by Caspase-8 Blockade in Different NSCLC Cell Lines.
We further investigated whether the findings that indicated a central role for caspase-8 in chemotherapy-induced apoptosis in H460 cells would apply also to other NSCLC cell lines. Therefore, H460 cells, together with the NSCLC cell lines H322 and SW1573, were exposed to both cisplatin and the preferential caspase-8 inhibitor IETD-fmk. The extent of blockade of drug-induced apoptosis was analyzed in comparison with the effect obtained with the broad-spectrum caspase inhibitor zVAD-fmk. Jurkat-T-leukemia cells were selected for use in these experiments as a control, because the pattern of inhibition of chemotherapy-induced apoptosis provided by IETD-fmk and zVAD-fmk has been reported in these cells (31 , 45) . As shown in Fig. 7ACitation , a similar pattern of suppression of chemotherapy-induced apoptosis (50–60%) was provided by IETD-fmk in all of the three NSCLC lines analyzed (P = 0.025). Interestingly, the protection provided by IETD-fmk was similar to the blockade obtained with the pancaspase inhibitor zVAD-fmk, which again suggested a crucial role of caspase-8 (Fig. 7A)Citation . In contrast, in Jurkat cells, IETD-fmk provided no protection (P = 0.2), whereas zVAD-fmk blocked at least 85% of drug-induced apoptosis (P = 0.006). These results were reproducible on using other drugs (topotecan or gemcitabine), concentrations (IC50 or IC80), or time point for analysis (data not shown). We also analyzed the cleavage of IETD-AFC as a marker of caspase-8 activity in the NSCLC cell lines H460, H322, and SW1573 during cisplatin- and Fas-induced apoptosis. The findings were then compared with the results observed in Jurkat cells under the same experimental conditions. Fas-induced death was used as a marker for caspase-8 activity during apoptosis. As shown in Fig. 7BCitation , the amount of IETD-AFC cleavage generated during cisplatin and Fas-induced apoptosis was similarly high in all of the three NSCLC cell lines analyzed. In contrast, in Jurkat cells, Fas exposure led to a substantial increase in IETD-AFC cleavage, whereas exposure to cisplatin had hardly any effect on caspase-8 activity (Fig. 7B)Citation . These results are consistent with the findings observed with the caspase-inhibitor IETD-fmk. We thus conclude that our findings pointing to an important role for caspase-8 in chemotherapy-induced apoptosis in H460 cells can be likely extrapolated to other NSCLC cells.

Blocking Caspase-8 Favors Clonogenic Survival in H460 Cells on Drug Treatment.
Finally, to further examine the relevance of caspase-8 in drug-induced cytotoxicity in H460 cells, we questioned whether the inhibition of this caspase would simply delay cell death or whether it would be able to rescue cells, favoring clonogenic survival. Clonogenic growth assays were performed in which control vector-transfected cells, together with CrmA and caspase-8-DN overexpressing cells, were exposed to IC50 and IC80 concentrations of anticancer drugs. CrmA- and caspase-8-DN-expressing cells showed a significant increase in clonogenic potential when compared with cells transfected with the empty vector or the parental line (Table 2Citation ; P = 0.015 and 0.025, respectively). Similar observations were made in H460 cells overexpressing Bcl-2 or Bcl-xL (P = 0.006). In contrast, stable expression of the caspase-9 inhibitors, caspase-9S and XIAP, did not increase clonogenic survival (Table 2)Citation , being consistent with their inability to suppress drug-induced apoptosis.


View this table:
[in this window]
[in a new window]
  		Table 2 Clonogenic survival of H460 cells transfected either with caspase-8 and -9 and mitochondria inhibitors or with the respective empty vectors

Cells were exposed to IC80 concentrations of the anticancer drugs for 48 h.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Caspase-8 Is the Apical Caspase in Drug-induced Apoptosis in H460 Cells.
Studies to unravel the molecular basis of chemoresistance in tumor cells may help to design new strategies for cancer treatment. In this respect, great progress has been made in the understanding of the pathways that underlie chemotherapy-induced apoptosis, in which the sequential activation of caspases has been found to be required for the execution phase of the apoptotic process. A model has been proposed in which two different caspases, caspase-8 and -9, mediate distinct types of apoptotic stimuli: caspase-8 being the apical caspase in death-receptor-induced apoptosis, and caspase-9 being activated on anticancer drug treatment (7, 8, 9, 10) . Although this model may explain the situation found in leukemia cells, it is not clear whether it can be applied to apoptotic responses triggered in solid tumors cells. In this study, we have investigated the involvement of caspase-8- and -9-dependent pathways in chemotherapy-induced apoptosis in NSCLC cell line H460.

Different lines of experimentation clearly indicate the importance and apical role of caspase-8 and the lack of function of caspase-9 in chemotherapy-induced apoptosis in H460 cells. Firstly, stable overexpression of the caspase-9 inhibitors caspase-9S and XIAP in the NSCLC cell line H460 failed to suppress apoptosis that was induced by various chemotherapeutic drugs, which correlated with the observed lack of caspase-9 activity in these cells (Fig. 1)Citation . Secondly, drug-induced apoptosis was blocked in H460 transfectants that expressed known inhibitors of caspase-8, e.g., CrmA and caspase-8 DN (Fig. 2)Citation . These results are in line with the observation that the preferential caspase-8 peptide-inhibitor IETD-fmk blocked druginduced apoptosis in NSCLC cells (Fig. 7A)Citation . The similar blockade of drug-induced apoptosis induced by IETD-fmk and the substantial amount of cleavage of IETD-AFC generated by exposure to chemotherapy in three distinct NSCLC cell lines suggest that our results may be characteristic of NSCLC cells, rather than being cell type-specific phenomena related to H460 cells. In addition, these findings are in contrast to the results obtained with drug-induced apoptosis in Jurkat cells, which we included as control in our studies (Figs. 1Citation and 7)Citation . These findings in Jurkat cells are in line with a previous report in HL-60 cells (31) . Our findings in H460 cells expressing CrmA are at odds with the reported lack of suppression of drug-dependent apoptosis by CrmA in lymphoid cells (32 , 47) but are in line with another report showing a blockage of drug-induced by CrmA in leukemia cells (48) . A possible explanation for this discrepancy may be an effect of CrmA on other caspases. In fact, when analyzing our results, we have to take into consideration that both CrmA and chemical caspase inhibitors like IETD-fmk have been shown to inhibit caspases other than caspase-8 in cell-free systems (44) . However, the confirmation of our findings in H460 cells overexpressing caspase-8-DN gives weight to our data and point to a crucial role of caspase-8 in the process of drug-induced apoptosis in the NSCLC cell line H460.

Some investigators have reported the activation of procaspase 8 in drug-induced apoptosis. However, in these studies, the activation of caspase-8 by chemotherapy appeared to be a mere bystander effect and not a key event in the execution of the apoptotic program (29, 30, 31 , 49) . An alternative pathway for chemotherapy-dependent activation of caspase-8 has been proposed in leukemia, neuroblastoma, and colon cancer cells and would be based on Fas/FasL signaling (50, 51, 52) . However, we and others have been unable to substantiate this model (30 , 38 , 45 , 53, 54, 55) ; and, moreover, our current finding that drug-induced apoptosis in H460 cells is not inhibited by FADD-DN overexpression further demonstrates that death receptors are not involved in mediating this response (Fig. 3)Citation . In H460 cells, caspase-8 activation appears to be an apical event in the execution phase, because we conclude from our finding that this activation precedes the chemotherapy-mediated increase in caspase-3-like activity and the PARP cleavage that take place independently from caspase-9 activation (Figs. 1Citation and 6)Citation .

Caspase-8 Activation in H460 Cells Is Mitochondria-dependent.
In analogy with the mechanisms that can activate caspase-9, we studied the role of mitochondria in drug-dependent caspase-8 activation in H460 cells. On the basis of the following observations, we conclude that this activation requires a mitochondrial step (see Fig. 4Citation ): (a) overexpression of Bcl-2 and Bcl-xL blocks caspase-8 cleavage as well as IETD-AFC proteolytic activity; (b) overexpression of the caspase-8 inhibitors CrmA and caspase-8-DN fails to block cytochrome c release from mitochondria after exposure to chemotherapy; and (c) IETD-fmk and zVAD-fmk do not block cytochrome c release.

We are aware of one earlier report (56) describing mitochondria-controlled caspase-8 cleavage in neuroblastoma cells in which, on exposure to betulinic acid, caspase-8 was activated by apoptosis-inducing factor. Furthermore, in analogy with the mechanism of drug-dependent caspase-9 activation, a possibility would be that Apaf-1, together with cytochrome c and caspase-8 could form an alternative apoptosomal complex. This possibility is not unprecedented, inasmuch as caspase-8 has been found to be able to interact with Apaf-1, although these findings are under dispute (29 , 57) . In addition, caspase-8 has been shown to be able to cleave and, thus, activate all known caspases in vitro (58) , which may be taken as an additional evidence for its candidacy as an initiator caspase in death-receptor-independent types of apoptosis (7) . We are presently further exploring this potential mechanism of caspase-8 activation in NSCLC cells. Another question to be addressed is why NSCLC cells use a caspase-8-dependent pathway instead of the more commonly used caspase-9 route. When we take into consideration that caspase-9 and Apaf-1 are expressed at normal levels in H460 cells (Fig. 1D)Citation , our findings suggest that caspase-9 itself or some component of the complex that is responsible for its activation may be constitutionally inhibited or nonfunctional in H460 cells. To the best of our knowledge, the present report provides the first indication for the existence of a constitutional mechanism of inhibition at this level in cancer cells. Possible means that render caspase-9 nonfunctional in these cells are currently under investigation in our laboratory.

Implications of caspase-8-mediated Apoptosis in the Treatment of NSCLC.
An important issue that is disputed in cancer research concerns the correlation between chemotherapy-induced apoptosis and clonogenic survival (59) . Controversial data have been generated not only about upstream members of the death machinery—such as p53, p21, and c-myc (9 , 60, 61, 62) —but also about caspases. The use of peptide inhibitors of caspases was shown to abrogate the morphological hallmarks of apoptosis; however, peptide inhibitors failed to interfere with the final commitment of cells to die (63) . In contrast, a correlation between apoptosis and clonogenic survival has been reported in cells overexpressing CrmA (32) . In this study, we also found a close correlation between the suppressive effect of overexpression of the caspase-8 inhibitors, caspase-8-DN, and CrmA, on drug-induced cell death and the clonogenic outgrowth of H460 cells. Taken into a broader perspective, our results suggest that constitutional mechanisms of caspase inhibition may have a considerable impact on the resistance of cancer cells to chemotherapy, because, upon caspase blockade, cells were allowed to proliferate and were not doomed to die by an alternative or delayed mechanism.

In conclusion, our findings in H460 cells provide a novel picture of the events involved in the apoptosis induced by anticancer agents that challenges the assumption that chemotherapy-induced apoptosis is preferentially mediated in a caspase-9-dependent manner. We demonstrate that after mitochondria activation by anticancer drugs, caspase-8 is activated in a caspase-9-independent manner, and, in turn, mediates the activation of effector caspases leading to apoptosis. In fact, because of differences from the model reported in other cell types, our data suggest that the caspase pathway activated might vary not only according to the sort of stimuli, but also depending on the cellular context, as proposed previously (9) . These findings may help to explain the difference in chemosensitivity between NSCLC cells and leukemia cell lines cells, and it would be particularly interesting if these observations can be confirmed in other solid tumor lines.


   ACKNOWLEDGMENTS
 
We thank Drs. David L. Vaux and Andreas Strasser (The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia) for CrmA WT, loss-of-function CrmA, and Bcl-2/Bcl-xL expression plasmids, respectively; Dr. Claudio Vincenz (The University of Michigan Medical School, Ann Arbor, MI) for FADD-DN and Flice-DN expression vectors; Dr. Kuni Matsumoto (Graduate School of Science, Nagoya University, Nagoya, Japan) for plasmid containing XIAP. We are also grateful to Dr. Xiadong Wang (University of Texas Southwestern Medical Center, Dallas, TX) for Apaf-1 antibody.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 C. G. F. is supported by a personal grant from Capes (Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) Brasília, Brazil. Back

2 To whom requests for reprints should be addressed, at the Department of Medical Oncology, University Hospital Vrije Universiteit, De Boelelaan 1117, 1081HV Amsterdam, the Netherlands. Phone: 31-20-444-4300; Fax: 31-20-444-4079; E-mail: g.giaccone{at}azvu.nl Back

3 The abbreviations used are: NSCLC, non-small cell lung cancer; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; FADD, Fas-associated death domain; IAP, apoptosis-inhibiting protein; XIAP, X-linked IAP; CrmA, cytokine response modifier A; AFC, 7-amino-4-trifluoromethyl coumarin; DEVD-AFC, benzyloxycarbonyl-Asp-Glu-Val-APC; IETD-AFC, benzyloxycarbonyl-Ileu-Glu-Thr-Asp-AFC; zVAD-fmk, carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone; IETD-fmk, Z-lle-Glu(Ome)-Thr-Asp(Ome)-fluoromethyl ketone; Apaf-1, apoptotic protease-activating factor 1; NCI-H460, H460; DN, dominant negative; WT, wild type; PI, propidium iodide; 7-AAD, 7-amino-actinomycin D; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; mAb. monoclonal antibody; FasL, Fas ligand; PARP, poly(ADP-ribose) polymerase; caspase-9S, caspase-9 short form. Back

Received 4/18/00. Accepted 10/30/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bunn P. A. J., Vokes E. E., Langer C. J., Schiller J. H. An update on North American randomized studies in non-small cell lung cancer. Semin. Oncol., 25: 2-10, 1998.
  2. Fisher D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.[Medline]
  3. Alnemri E. S., Livingston D. J., Nicholson D. W., Salvesen G., Thornberry N. A., Wong W. W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell, 87: 171 1996.[Medline]
  4. Cohen G. M. Caspases: the executioners of apoptosis. Biochem. J., 326: 1-16, 1997.
  5. Thornberry N. A., Lazebnik Y. Caspases: enemies within. Science (Washington DC), 281: 1312-1316, 1998.[Abstract/Free Full Text]
  6. Nunez G., Benedict M. A., Hu Y., Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene, 17: 3237-3245, 1998.[Medline]
  7. Sun X. M., MacFarlane M., Zhuang J., Wolf B. B., Green D. R., Cohen G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem., 274: 5053-5060, 1999.[Abstract/Free Full Text]
  8. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 15: 269-290, 1999.[Medline]
  9. Hakem R., Hakem A., Duncan G. S., Henderson J. T., Woo M., Soengas M. S., Elia A., de la Pompa J. L., Kagi D., Khoo W., Potter J., Yoshida R., Kaufman S. A., Lowe S. W., Penninger J. M., Mak T. W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell, 94: 339-352, 1998.[Medline]
  10. Zhuang J., Cohen G. M. Release of mitochondrial cytochrome c is upstream of caspase activation in chemical-induced apoptosis in human monocytic tumour cells. Toxicol. Lett., 102–103: 121-129, 1998.
  11. Boldin M. P., Goncharov T. M., Goltsev Y. V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell, 85: 803-815, 1996.[Medline]
  12. Muzio M., Salvesen G. S., Dixit V. M. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J. Biol. Chem., 272: 2952-2956, 1997.[Abstract/Free Full Text]
  13. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K. J., Debatin K. M., Krammer P. H., Peter M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 17: 1675-1687, 1998.[Medline]
  14. Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmad M., Alnemri E. S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.[Medline]
  15. Zou H., Li Y., Liu X., Wang X. An APAF-1. cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem., 274: 11549-11556, 1999.[Abstract/Free Full Text]
  16. Srinivasula S. M., Ahmad M., Fernandes-Alnemri T., Alnemri E. S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell, 1: 949-957, 1998.[Medline]
  17. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis [published erratum appears in Nat. Med., 3: 934, 1997]. Nat. Med., 3: 614-620, 1997.[Medline]
  18. Dole M., Nunez G., Merchant A. K., Maybaum J., Rode C. K., Bloch C. A., Castle V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res., 54: 3253-3259, 1994.[Abstract/Free Full Text]
  19. Dole M. G., Jasty R., Cooper M. J., Thompson C. B., Nunez G., Castle V. P. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy- induced apoptosis. Cancer Res., 55: 2576-2582, 1995.[Abstract/Free Full Text]
  20. Bossy-Wetzel E., Newmeyer D. D., Green D. R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD- specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J., 17: 37-49, 1998.[Medline]
  21. Zamzami N., Susin S. A., Marchetti P., Hirsch T., Gomez-Monterrey I., Castedo M., Kroemer G. Mitochondrial control of nuclear apoptosis. J. Exp. Med., 183: 1533-1544, 1996.[Abstract/Free Full Text]
  22. Kluck R. M., Bossy-Wetzel E., Green D. R., Newmeyer D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Washington DC), 275: 1132-1136, 1997.[Abstract/Free Full Text]
  23. Zhou Q., Snipas S., Orth K., Muzio M., Dixit V. M., Salvesen G. S. Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J. Biol. Chem., 272: 7797-7800, 1997.[Abstract/Free Full Text]
  24. Bump N. J., Hackett M., Hugunin M., Seshagiri S., Brady K., Chen P., Ferenz C., Franklin S., Ghayur T., Li P. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science (Washington DC), 269: 1885-1888, 1995.[Abstract/Free Full Text]
  25. Deveraux Q. L., Takahashi R., Salvesen G. S., Reed J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature (Lond.), 388: 300-304, 1997.[Medline]
  26. Roy N., Deveraux Q. L., Takahashi R., Salvesen G. S., Reed J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J., 16: 6914-6925, 1997.[Medline]
  27. Ambrosini G., Adida C., Altieri D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3: 917-921, 1997.[Medline]
  28. Deveraux Q. L., Leo E., Stennicke H. R., Welsh K., Salvesen G. S., Reed J. C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J., 18: 5242-5251, 1999.[Medline]
  29. Slee E. A., Harte M. T., Kluck R. M., Wolf B. B., Casiano C. A., Newmeyer D. D., Wang H. G., Reed J. C., Nicholson D. W., Alnemri E. S., Green D. R., Martin S. J. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol., 144: 281-292, 1999.[Abstract/Free Full Text]
  30. Boesen-de C. J., Tepper A. D., de Vries E., van Blitterswijk W. J., Borst J. Common regulation of apoptosis signaling induced by CD95 and the DNA- damaging stimuli etoposide and {gamma}-radiation downstream from caspase- 8 activation. J. Biol. Chem., 274: 14255-14261, 1999.[Abstract/Free Full Text]
  31. Perkins C., Kim C. N., Fang G., Bhalla K. N. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res., 58: 4561-4566, 1998.[Abstract/Free Full Text]
  32. Ekert P. G., Silke J., Vaux D. L. Inhibition of apoptosis and clonogenic survival of cells expressing crmA variants: optimal caspase substrates are not necessarily optimal inhibitors. EMBO J., 18: 330-338, 1999.[Medline]
  33. Huang D. C., Cory S., Strasser A. Bcl-2, Bcl-xL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene, 14: 405-414, 1997.[Medline]
  34. Seol D. W., Billiar T. R. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J. Biol. Chem., 274: 2072-2076, 1999.[Abstract/Free Full Text]
  35. Chinnaiyan A. M., O’Rourke K., Yu G. L., Lyons R. H., Garg M., Duan D. R., Xing L., Gentz R., Ni J., Dixit V. M. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science (Washington DC), 274: 990-992, 1996.[Abstract/Free Full Text]
  36. Chinnaiyan A. M., O’Rourke K., Tewari M., Dixit V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81: 505-512, 1995.[Medline]
  37. Yamaguchi K., Nagai S., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K., Ueno N., Nishida E., Shibuya H., Matsumoto K. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J., 18: 179-187, 1999.[Medline]
  38. Ferreira C. G., Tolis C., Span S. W., Peters G. J., van Lopik T., Kummer A. J., Pinedo H. M., Giaccone G. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin. Cancer Res., 6: 203-212, 2000.[Abstract/Free Full Text]
  39. Nicoletti I., Migliorati G., Pagliacci M. C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.[Medline]
  40. Peters G. J., van Dijk J., Laurensse E., van Groeningen C. J., Lankelma J., Leyva A., Nadal J. C., Pinedo H. M. In vitro biochemical and in vivo biological studies of the uridine ‘rescue’ of 5-fluorouracil. Br. J. Cancer, 57: 259-265, 1988.[Medline]
  41. Tolis C., Peters G. J., Ferreira C. G., Pinedo H. M., Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur. J. Cancer, 35: 796-807, 1999.
  42. Fadeel B., Hassan Z., Hellstrom-Lindberg E., Henter J. I., Orrenius S., Zhivotovsky B. Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells. Leukemia, 13: 719-728, 1999.[Medline]
  43. Newton K., Harris A. W., Bath M. L., Smith K. C., Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J., 17: 706-718, 1998.[Medline]
  44. Garcia-Calvo M., Peterson E. P., Leiting B., Ruel R., Nicholson D. W., Thornberry N. A. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem., 273: 32608-32613, 1998.[Abstract/Free Full Text]
  45. Wesselborg S., Engels I. H., Rossmann E., Los M., Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood, 93: 3053-3063, 1999.[Abstract/Free Full Text]
  46. Wajant H., Johannes F. J., Haas E., Siemienski K., Schwenzer R., Schubert G., Weiss T., Grell M., Scheurich P. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1-, and TRAIL-R/Apo2- mediated cell death but not gene induction. Curr. Biol., 8: 113-116, 1998.[Medline]
  47. Strasser A., Harris A. W., Huang D. C., Krammer P. H., Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J., 14: 6136-6147, 1995.[Medline]
  48. Antoku K., Liu Z., Johnson D. E. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia, 11: 1665-1672, 1997.[Medline]
  49. King D., Pringle J. H., Hutchinson M., Cohen G. M. Processing/activation of caspases, -3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells. Leukemia, 12: 1553-1560, 1998.[Medline]
  50. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res., 57: 3823-3829, 1997.[Abstract/Free Full Text]
  51. Houghton J. A., Harwood F. G., Tillman D. M. Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc. Natl. Acad. Sci. USA, 94: 8144-8149, 1997.[Abstract/Free Full Text]
  52. Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug- induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.[Medline]
  53. Eischen C. M., Kottke T. J., Martins L. M., Basi G. S., Tung J. S., Earnshaw W. C., Leibson P. J., Kaufmann S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90: 935-943, 1997.[Abstract/Free Full Text]
  54. Ferrari D., Stepczynska A., Los M., Wesselborg S., Schulze-Osthoff K. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J. Exp. Med., 188: 979-984, 1998.[Abstract/Free Full Text]
  55. Villunger A., Egle A., Kos M., Hartmann B. L., Geley S., Kofler R., Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res., 57: 3331-3334, 1997.[Abstract/Free Full Text]
  56. Fulda S., Scaffidi C., Susin S. A., Krammer P. H., Kroemer G., Peter M. E., Debatin K. M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem., 273: 33942-33948, 1998.[Abstract/Free Full Text]
  57. Hu Y., Benedict M. A., Wu D., Inohara N., Nunez G. Bcl-xL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. USA, 95: 4386-4391, 1998.[Abstract/Free Full Text]
  58. Srinivasula S. M., Ahmad M., Fernandes-Alnemri T., Litwack G., Alnemri E. S. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. USA, 93: 14486-14491, 1996.[Abstract/Free Full Text]
  59. Brown J. M., Wouters B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res., 59: 1391-1399, 1999.[Abstract/Free Full Text]
  60. Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B., Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.[Medline]
  61. Han J. W., Dionne C. A., Kedersha N. L., Goldmacher V. S. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Res., 57: 176-182, 1997.[Abstract/Free Full Text]
  62. Weinstein J. N., Myers T. G., O’Connor P. M., Friend S. H., Fornace A. J. J., Kohn K. W., Fojo T., Bates S. E., Rubinstein L. V., Anderson N. L., Buolamwini J. K., van Osdol W. W., Monks A. P., Scudiero D. A., Sausville E. A., Zaharevitz D. W., Bunow B., Viswanadhan V. N., Johnson G. S., Wittes R. E., Paull K. D. An information-intensive approach to the molecular pharmacology of cancer. Science (Washington DC), 275: 343-349, 1997.[Abstract/Free Full Text]
  63. Flomerfelt F. A., Miesfeld R. L. Recessive mutations in a common pathway block thymocyte apoptosis induced by multiple signals. J. Cell Biol., 127: 1729-1742, 1994.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Hum Exp ToxicolHome page
T. Yeo, J Kintner, R Armand, R Perez, and L. Lewis
Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells
Human and Experimental Toxicology, December 1, 2007; 26(12): 911 - 921.
[Abstract] [PDF]